Search

Your search keyword '"Estrada, Vicente"' showing total 583 results

Search Constraints

Start Over You searched for: Author "Estrada, Vicente" Remove constraint Author: "Estrada, Vicente"
583 results on '"Estrada, Vicente"'

Search Results

2. Monkeypox virus genomic accordion strategies

3. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

4. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

5. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

7. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

9. Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects

10. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort

12. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

13. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

14. A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19.

15. Predictors of poor prognosis in healthy, young, individuals with SARS-CoV-2 infections

16. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

17. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

18. Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry

19. Fibrilación auricular en pacientes con COVID-19. Utilidad de la puntuación CHA2DS2-VASc: un análisis del registro internacional HOPE COVID-19

20. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

21. Does there exist an obesity paradox in COVID-19? Insights of the international HOPE-COVID-19-registry

22. Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases

23. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

24. Interactions among the mycobiome, bacteriome, inflammation, and diet in people living with HIV

26. Clinical presentation, therapeutic approach, and outcome of young patients admitted for COVID-19, with respect to the elderly counterpart

27. Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design

28. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

30. Mpox, herpes, and enteroviruses: Differential diagnosis

31. Transcriptional signature of resting-memory CD4 T cells differentiates spontaneous from treatment-induced HIV control

34. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

35. T Cell Homeostasis Disturbances in a Cohort of Long-Term Elite Controllers of HIV Infection.

36. A specific natural killer cells phenotypic signature associated to long term elite control of HIV infection.

42. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

44. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

45. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

46. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

49. Faster lung function decline in people living with HIV despite adequate treatment:a longitudinal matched cohort study

50. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors

Catalog

Books, media, physical & digital resources